Soft capsule technology: modified pea starch as a vegetal origin alternative to gelatin in capsule shell
The latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin.
Gelatin has been used as shell polymer in the manufacture of soft gelatin capsules (softgels) for about the past century. Its rheological and thermal properties offer adequate balance for subsequent process steps including gel solution preparation/transportation, film casting, and capsule sealing/drying.
Even though this material represents the current gold standard for soft capsules, it presents certain technical challenges such as cross-linking. In other words, it may react with some capsule active fills during storage, leading to a delay in the release time. Moreover, gelatin-based soft capsules are sensitive to heat during production, as well as during storage. Finally, both the cross-linking tendency and heat sensitivity limit the options for fill materials, especially those requiring higher processing temperatures.
Multiple vegetal origin materials were investigated as potential replacement for gelatin. Various modified starches (corn, tapioca, etc.), alone or in combination with some hydrocolloids (carrageenan, alginates, gellan gum, etc.) were used to develop non-gelatin shell formulations over the last two decades. Some of the existing commercial options are associated with important initial investment such as the need to modify the equipment (tumble dryers, etc.), or to buy special feature parts (gel mixer, spreader boxes, etc.). From a process standpoint, they are also often associated with limitations such as lower production speed, longer drying time, and capsule defects like leakage or stickiness in comparison with gelatin.
Riding the wave of sustainability, “vegan” or “clean label,” pharmaceutical and nutraceutical companies are now trying to combine the best of both worlds. Actually, they are looking at vegetarian alternatives that display similar or even higher technical performance than gelatin for the production of soft capsules: using standard equipment at full speed, to deliver optimal capsules with additional fill material options and better stability.
See the full white paper here.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance